GlobeNewswire by notified

DSV, 995 - SHARE BUYBACK IN DSV A/S

Share

Company Announcement No. 995

On 25 October 2022, we initiated a share buyback programme, as described in Company Announcement No. 992. According to the programme, the company will in the period from 25 October 2022 until 14 November 2022 purchase own shares up to a maximum value of DKK 3,000 million, and no more than 5,000,000 shares, corresponding to 2.14% of the current share capital of DSV A/S. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5).

Trading dayNumber of shares bought backAverage transaction priceAmount DKK
Accumulated trading for days 1-4930,0001,010.35939,621,850
5:31 October 2022212,0001,020.43216,331,160
6:1 November 2022220,0001,026.60225,852,000
7:2 November 2022170,0001,010.60171,802,000
8:3 November 2022298,0001,001.86298,554,280
9:4 November 2022170,0001,024.56174,175,200
Accumulated trading for days 1-92,000,0001,013.172,026,336,490

After the disclosed transactions, DSV A/S holds a total of 13,840,533 shares of a nominal value of DKK 1 in DSV A/S, corresponding to 5.91% of the total number of issued shares of 234,000,000.

The details of each transaction made under the share buyback programme are published on investor.dsv.com.

Any questions may be addressed to Executive Vice President, Investor Relations, Flemming Ole Nielsen, tel. +45 43 20 33 92.

Yours sincerely,
DSV A/S

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Konsolidator completes private placement3.5.2024 10:31:01 CEST | Press release

Company announcement no 10-2024 Søborg, May 3, 2024 Konsolidator completes private placement In company announcement no. 9-2024, Konsolidator A/S (“Konsolidator”) announced the resolution by the Board of Directors to issue up to 1,685,394 new shares in a private placement. The new shares have been subscribed for by 11 private investors, including all members of the Board of Directors, the CEO, Claus Finderup Grove and CFO, Jack Skov. Konsolidator announces the completion of the private placement as all 1,685,394 new shares have been subscribed for and the total subscription amount of DKK 6m has been received by Konsolidator, corresponding to a net proceeds of DKK 5.9m. Today, the new shares and the related capital increase has been registered at the Danish Business Authority, following which the company has a registered share capital of nominal DKK 886,428.84. The share capital will consist of 22,160,721 shares, each with a nominal value of DKK 0.04. Each share carries one vote, corres

RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS3.5.2024 10:05:00 CEST | Press release

Auction date2024-05-03Loan1059Coupon1.00 %ISIN-codeSE0007125927Maturity2026-11-12Tendered volume, SEK mln1,000 +/- 1,000Total bid volume, SEK mln3,100 Volume sold, SEK mln1,000 Number of bids9 Number of accepted bids1 Average yield2.831 %Lowest yield2.831 %Highest accepted yield2.831 %% accepted at highest yield 100.00 Auction date2024-05-03Loan1063Coupon0.50 %ISIN-codeSE0015193313Maturity2045-11-24Tendered volume, SEK mln900 +/- 900Total bid volume, SEK mln3,492 Volume sold, SEK mln900 Number of bids37 Number of accepted bids8 Average yield2.526 %Lowest yield2.517 %Highest accepted yield2.529 %% accepted at highest yield 11.63

Danske Bank A/S, transactions by persons discharging managerial responsibilities3.5.2024 10:02:35 CEST | Press release

3 May 2024 Notification no. 46/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024.05.02

Danske Bank A/S, ledende medarbejderes transaktioner3.5.2024 10:02:35 CEST | pressemeddelelse

3. maj 2024 Indberetning nr. 46/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024.05.02

PCI Biotech Holding ASA - Notice of Annual General Meeting 20243.5.2024 10:00:00 CEST | Press release

Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website www.pcibiotech.com. For further information, please contact: Ronny Skuggedal, CEO/CFO, E-mail: rs@pcibiotech.no Office: +47 67 11 54 00 Mobile: +47 94 00 57 57 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments PCI Biotech Innkalling GF 2024PCI Biotech Forslag til beslutninger GF 2024PCI Biotech Notice of AGM 2024PCI Biotech Proposed resolutions for the AGM 2024

HiddenA line styled icon from Orion Icon Library.Eye